Developer docs
API playgroundTry for free, no card

Search company profiles

TECLens

Full company profile

uuid00025f1

Namestring
TECLens
Legal namestring
TECLens, Inc.
Websiteurl
teclens.com
Company typeenum
Private
Founded yearint
2013
Descriptiontext

TECLens is a clinical-stage medical device company developing a non-invasive approach to strengthening and reshaping the cornea for presbyopia and other refractive errors. It is also evaluating applications in hyperopia, adult and pediatric myopia, astigmatism, and keratoconus, with current activity centered on clinical development rather than commercial scale-up. Primary evidence:.

The qCXL platform uses personalized computational biomechanics treatment planning, patterned ultraviolet light delivered through a fiber optic-connected, single-use scleral contact lens called CXLens, and real-time ultrasound monitoring for closed-loop control. The system also includes a control console, UV and ultrasound hardware, proprietary trans-epithelial riboflavin, and treatment-planning software. TECLens states that the procedure does not cut or remove corneal tissue. Primary evidence:.

The planned business model combines capital-equipment sales for the control console with recurring per-procedure sales of disposable CXLens devices and riboflavin. TECLens plans direct B2B sales to ophthalmologists, optometrists, and eye-care practices, supported by training and clinical support, with procedures intended for an exam-room setting. Pricing, installed base, utilization, and current revenue are not disclosed. Primary evidence:.

Short descriptiontext

TECLens is a clinical-stage medical device company developing qCXL, a non-invasive corneal cross-linking platform that uses personalized planning, patterned UV light, and real-time ultrasound to reshape the cornea for presbyopia and other refractive errors.

Operating statusenum
Operating
Ownership categoryenum
Headcount rangeband
11–50
akta.pro rankint
HeadquartersStamford, United States
HQ citystring
Stamford
HQ countrystring
United States
HQ regionstring
North America
Markets served

Serves global market

Offices2 records

Each record includes

City, Country, Type, Description, Source

Keyword5 values
corneal cross-linking, refractive vision correction, ophthalmic medical devices, keratoconus treatment, presbyopia correction
Industry5 codes
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAG
Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)
SECONDARYHLAHAJAE
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)
NAICS code2 codes
  • Ophthalmic Goods Manufacturing339115
  • Surgical and Medical Instrument Manufacturing339112
SIC code2 codes
  • Ophthalmic Goods3851
  • Optical Instruments & Lenses3827
Product category
Ophthalmic Medical Devices
Social media profiles1 record
GTM motion1 record

Each record includes

Type, Description, Source

Revenue model2 records
1Medical Device Sales
TypeHardware Sales
Description

TECLens generates revenue through the sale of its CXLens® system - a capital equipment console and single-use disposable devices. The system includes a control system console, disposable treatment delivery devices, and the riboflavin drug formulation. The company plans to serve eye care professionals with a low-cost entry system.

teclens.com
2Consumables
TypeHardware Sales
Description

Recurring revenue from single-use disposable contact lens devices (CXLens®) and proprietary riboflavin drug formulation used in each procedure.

teclens.com
Marketing channels5 records

Each record includes

Title, Type, Stage, Description, Source

Distribution channels2 records

Each record includes

Title, Type, Scope, Target buyer, Description, Source

Cost components5 values
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain
GTM typeB2B
B2B
Offering typeHardware or Manufacturing
Hardware or Manufacturing
Brand1 of 2 records shown
1qCXL™
Description

Quantitative Corneal Cross-Linking technology - proprietary technology designed to gently strengthen and reshape the cornea using ultraviolet light, addressing refractive errors including presbyopia.

teclens.com
+1 more record
Core offering1 text field

TECLens develops the qCXL™ system — a proprietary non-invasive corneal cross-linking platform centered on the single-use disposable CXLens® scleral contact lens, a control console, a proprietary trans-epithelial riboflavin formulation, and a computational treatment planning suite. The platform uses patterned ultraviolet light combined with real-time ultrasound monitoring to strengthen and reshape the cornea, addressing refractive errors (presbyopia, myopia, hyperopia, astigmatism) and keratoconus without cutting or removing tissue.

Differentiator
Functional benefit
Problem solved
Quantifiable outcome1 of 4 values shown
  • Nearly 2 billion people worldwide affected by presbyopia
+3 more records
Product overview1 text field

TECLens offers a unified platform-based product ecosystem centered on its qCXL (Quantitative Corneal Cross-Linking) technology. The core system consists of four integrated components: the CXLens single-use disposable device (a fiber optic-connected scleral contact lens that delivers UV light), the Control Console (user interface with computer, UV and ultrasound systems), a proprietary trans-epithelial riboflavin photoactive drug, and a Computational Treatment Planning Suite (software that creates personalized treatment plans and monitors execution). These components work together as an integrated system for non-invasive corneal reshaping, with initial focus on presbyopia correction and applications for myopia, hyperopia, astigmatism, and keratoconus.

Scale indicator6 records

Each record includes

Type, Value, Description, Source

Partnership2 partners
Strategic tierCoreTypeStrategic or Co-development PartnerAnnounced on2019-10-07
Description

Strategic partnership to pursue U.S. FDA approval for trans-epithelial corneal cross-linking. Combines TECLens' CXLens® on-eye cross-linking system with SERVImed's RIBOCROSS riboflavin drug formulation. SERVImed holds FDA orphan drug designation for RIBOCROSS. Partnership aims to provide comfortable, non-invasive treatment for keratoconus and ectatic disorders.

Strategic tierCoreTypeStrategic or Co-development Partner
Description

Clinical trial partner with Dr. Robert Ang, Refractive Surgery, Cataract, and Glaucoma Specialist, serving as Principal Clinical Study Investigator. Dr. Ang presented at Innovators Pop-Up during AAO 2025.

Recent move5 records

Each record includes

Date, Type, Title, Description, Source

Expansion highlight8 records

Each record includes

Type, Description

Peers10 records
TypeDirect peer
Description

Glaukos acquired Avedro, the historical leader in corneal collagen cross-linking (CXL) systems and riboflavin formulations. Both companies are working in the same therapeutic modality (CXL for keratoconus and refractive indications) and target the same ophthalmologist customer base, making them the most direct peer to TECLens.

2Peschke Medizintechnik
TypeDirect peer
Description

European manufacturer of CXL systems (C-Eye and predecessors) and riboflavin solutions for corneal cross-linking. Peschke competes head-to-head in the same therapeutic category as TECLens, with similar UVA illumination platforms and riboflavin formulations, primarily in EU markets.

3Sooft Italia
TypeDirect peer
Description

Italian ophthalmic company selling riboflavin (Ricrolin) and other CXL adjuncts across Europe. Comparable to TECLens in supplying the photoactive drug component for trans-epithelial corneal cross-linking procedures.

4Carl Zeiss Meditec
TypeBroad incumbent
Description

Global leader in refractive surgical lasers (VISUMAX femtosecond for SMILE/LASIK) and ophthalmic diagnostics. Competes for refractive correction procedure volumes against TECLens across LASIK/SMILE despite operating an entirely different (tissue-removing) modality.

TypeBroad incumbent
Description

World's largest ophthalmic surgical company with WaveLight excimer and Contoura platforms for refractive surgery. As the dominant incumbent in vision correction, Alcon defines the standard of care TECLens aims to disrupt non-invasively.

TypeBroad incumbent
Description

Refractive and cataract surgery franchise (iDesign, STAR S4 IR excimer, TECNIS IOLs) and TECLens's own strategic investor via JJDC. As both incumbent and shareholder, J&J Vision frames both the competitive set and a potential exit pathway for TECLens.

TypeDirect peer
Description

Swiss manufacturer of femtosecond lasers (LDV Z8) used in refractive and cataract surgery, with overlapping ophthalmic device DNA. Comparable in product engineering approach and physician-focused go-to-market.

TypeRegional player
Description

German manufacturer of excimer (AMARIS) and femtosecond lasers for refractive surgery. Strong in European refractive surgery markets where TECLens already has trial sites, making it a relevant competitive reference in shared geographies.

TypeBroad incumbent
Description

Major diversified ophthalmic company spanning contact lenses, IOLs (enVista, Toric), and LASIK excimer technology through Technolas. CTO Madhu Ayyagari's former employer; competes in refractive correction across multiple modalities.

TypeEmerging player
Description

US-based company commercializing the ALLY robotic cataract and refractive system, also pursuing presbyopia-correcting IOLs. Smaller, growth-stage competitor targeting overlapping refractive and presbyopia correction indications.

Market position
Strengths5 records

Each record includes

Headline, Details, Source

Weaknesses5 records

Each record includes

Headline, Details, Source

Competitive moat5 records

Each record includes

Type, Details

Key risks6 records

Each record includes

Headline, Details, Source

Key highlights7 records

Each record includes

Headline, Details, Source

Customer concentration

Classification, Details

Named customers3 records

Each record includes

Name, Industry, Type, Use case, Source, UUID

Segment4 records

Each record includes

Title, Type, Primary, Description, Pain point addressed, Use case, Source

Ideal customer profile2 records

Each record includes

Profile, Firmographic size, Sales motion, Sales cycle length, Buying structure, Purchase trigger, Buyer persona, Geography, Industry vertical, Primary use case, Description, Pain points, Evidence proof points, Target buyer

API detail
Has APIbool
No

Docs URL, Description

AI maturity
App detail

Has app

Feature6 records

Each record includes

Title, Differentiator, Description, Source

Core technology
Revenue estimate
Valuation estimate
Number of profiles
No data
No data
Funding overview

Funding stage, Last funding date, Total funding USD

Funding rounds5 records

Each record includes

Round, Amount USD, Date, Pre money valuation, Total investors, Investors, News

Investors4 records

Each record includes

Name, Type, Date of entry, Rounds participated, Website

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

M&A

Each record includes

Name, Acquisition type, Announced date, Completed date, Status, Website, News

Investment

Each record includes

Name, Round, Announced date, Lead investor, Website, News

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

TECLens

Ophthalmic Medical Devicesteclens.com

TECLens is a clinical-stage medical device company developing qCXL, a non-invasive corneal cross-linking platform that uses personalized planning, patterned UV light, and real-time ultrasound to reshape the cornea for presbyopia and other refractive errors.

What TECLens does

TECLens is a clinical-stage medical device company developing a non-invasive approach to strengthening and reshaping the cornea for presbyopia and other refractive errors. It is also evaluating applications in hyperopia, adult and pediatric myopia, astigmatism, and keratoconus, with current activity centered on clinical development rather than commercial scale-up. Primary evidence:.

The qCXL platform uses personalized computational biomechanics treatment planning, patterned ultraviolet light delivered through a fiber optic-connected, single-use scleral contact lens called CXLens, and real-time ultrasound monitoring for closed-loop control. The system also includes a control console, UV and ultrasound hardware, proprietary trans-epithelial riboflavin, and treatment-planning software. TECLens states that the procedure does not cut or remove corneal tissue. Primary evidence:.

The planned business model combines capital-equipment sales for the control console with recurring per-procedure sales of disposable CXLens devices and riboflavin. TECLens plans direct B2B sales to ophthalmologists, optometrists, and eye-care practices, supported by training and clinical support, with procedures intended for an exam-room setting. Pricing, installed base, utilization, and current revenue are not disclosed. Primary evidence:.

TECLens firmographics

Firmographics
Name
TECLens
Legal name
TECLens, Inc.
Website
https://teclens.com
Company type
Private
Founded year
2013
Operating status
Operating
Headcount range
11–50 employees
Short description
TECLens is a clinical-stage medical device company developing qCXL, a non-invasive corneal cross-linking platform that uses personalized planning, patterned UV light, and real-time ultrasound to reshape the cornea for presbyopia and other refractive errors.
Ownership category
akta.pro rank

TECLens industry classification

Industry
Product category
Ophthalmic Medical Devices
NAICS
Ophthalmic Goods Manufacturing (339115), Surgical and Medical Instrument Manufacturing (339112)
SIC
Ophthalmic Goods (3851), Optical Instruments & Lenses (3827)
akta.pro industry
PRIMARYHLAHAJAK
Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAJAG
Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAKAKAF
Cornea, External Disease & Refractive Surgery (LASIK/PRK)
SECONDARYHLAHAJAE
Contact Lenses & Care Systems (Soft/RGP/Scleral Lenses; Cleaning/Disinfection Solutions)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Ophthalmic Devices (Vision Care & Surgical)
SECONDARYHLAHAIAL
Ocular Drug Delivery Devices (Eye Droppers/Inserts)
Healthcare & Life Sciences/Medical Devices & Diagnostics/Drug Delivery Devices (Injectors, Pumps, Inhalers)

Keywords

  • Corneal cross-linking
  • Refractive vision correction
  • Ophthalmic medical devices
  • Keratoconus treatment
  • Presbyopia correction

Where TECLens is headquartered

Location

Headquarters

HQ city
Stamford
HQ country
United States
HQ region
North America

Offices2 records

Markets served

TECLens business model

Business model
GTM type
B2B
Offering type
Hardware or Manufacturing
Cost components
Technology or R&D, Personnel, Operations, Marketing or Sales, Supply Chain

Revenue model

  1. Medical Device Sales: TECLens generates revenue through the sale of its CXLens® system - a capital equipment console and single-use disposable devices. The system includes a control system console, disposable treatment delivery devices, and the riboflavin drug formulation. The company plans to serve eye care professionals with a low-cost entry system.
  2. Consumables: Recurring revenue from single-use disposable contact lens devices (CXLens®) and proprietary riboflavin drug formulation used in each procedure.

Go-to-market motion1 record

Distribution channels2 records

Marketing channels5 records

TECLens product offering

Product offering

Core offering

TECLens develops the qCXL™ system — a proprietary non-invasive corneal cross-linking platform centered on the single-use disposable CXLens® scleral contact lens, a control console, a proprietary trans-epithelial riboflavin formulation, and a computational treatment planning suite. The platform uses patterned ultraviolet light combined with real-time ultrasound monitoring to strengthen and reshape the cornea, addressing refractive errors (presbyopia, myopia, hyperopia, astigmatism) and keratoconus without cutting or removing tissue.

Product overview

TECLens offers a unified platform-based product ecosystem centered on its qCXL (Quantitative Corneal Cross-Linking) technology. The core system consists of four integrated components: the CXLens single-use disposable device (a fiber optic-connected scleral contact lens that delivers UV light), the Control Console (user interface with computer, UV and ultrasound systems), a proprietary trans-epithelial riboflavin photoactive drug, and a Computational Treatment Planning Suite (software that creates personalized treatment plans and monitors execution). These components work together as an integrated system for non-invasive corneal reshaping, with initial focus on presbyopia correction and applications for myopia, hyperopia, astigmatism, and keratoconus.

Differentiator

Problem solved

Functional benefit

Brands

  • qCXL™: Quantitative Corneal Cross-Linking technology - proprietary technology designed to gently strengthen and reshape the cornea using ultraviolet light, addressing refractive errors including presbyopia.
  • CXLens®

Quantifiable outcome

  • Nearly 2 billion people worldwide affected by presbyopia
  • +3 more outcomes

Companies that use TECLens

Customer profile

Named customers3 records

Segments4 records

Ideal customer profiles2 records

TECLens technology and API

Technology

API detail

Has API
No
API docs
API detail

Core technology

AI maturity

App detail

Feature6 records

TECLens partnerships and signals

Strategic signal

Partnerships

Two partnerships are on record, tiered core.

  • SERVImed Industrial SpacoreStrategic or Co-development Partner · 7 October 2019Strategic partnership to pursue U.S. FDA approval for trans-epithelial corneal cross-linking. Combines TECLens' CXLens® on-eye cross-linking system with SERVImed's RIBOCROSS riboflavin drug formulation. SERVImed holds FDA orphan drug designation for RIBOCROSS. Partnership aims to provide comfortable, non-invasive treatment for keratoconus and ectatic disorders.
  • Asian Eye InstitutecoreStrategic or Co-development PartnerClinical trial partner with Dr. Robert Ang, Refractive Surgery, Cataract, and Glaucoma Specialist, serving as Principal Clinical Study Investigator. Dr. Ang presented at Innovators Pop-Up during AAO 2025.

Scale indicators6 records

Recent moves5 records

Expansion highlights8 records

TECLens competitors and assessment

Company assessment

Direct peers

  • Glaukos Corporation (Avedro): Glaukos acquired Avedro, the historical leader in corneal collagen cross-linking (CXL) systems and riboflavin formulations. Both companies are working in the same therapeutic modality (CXL for keratoconus and refractive indications) and target the same ophthalmologist customer base, making them the most direct peer to TECLens.
  • Peschke Medizintechnik: European manufacturer of CXL systems (C-Eye and predecessors) and riboflavin solutions for corneal cross-linking. Peschke competes head-to-head in the same therapeutic category as TECLens, with similar UVA illumination platforms and riboflavin formulations, primarily in EU markets.
  • Sooft Italia: Italian ophthalmic company selling riboflavin (Ricrolin) and other CXL adjuncts across Europe. Comparable to TECLens in supplying the photoactive drug component for trans-epithelial corneal cross-linking procedures.
  • Ziemer Ophthalmic Systems: Swiss manufacturer of femtosecond lasers (LDV Z8) used in refractive and cataract surgery, with overlapping ophthalmic device DNA. Comparable in product engineering approach and physician-focused go-to-market.

Broad incumbents

  • Carl Zeiss Meditec: Global leader in refractive surgical lasers (VISUMAX femtosecond for SMILE/LASIK) and ophthalmic diagnostics. Competes for refractive correction procedure volumes against TECLens across LASIK/SMILE despite operating an entirely different (tissue-removing) modality.
  • Alcon: World's largest ophthalmic surgical company with WaveLight excimer and Contoura platforms for refractive surgery. As the dominant incumbent in vision correction, Alcon defines the standard of care TECLens aims to disrupt non-invasively.
  • Johnson & Johnson Vision: Refractive and cataract surgery franchise (iDesign, STAR S4 IR excimer, TECNIS IOLs) and TECLens's own strategic investor via JJDC. As both incumbent and shareholder, J&J Vision frames both the competitive set and a potential exit pathway for TECLens.
  • Bausch + Lomb: Major diversified ophthalmic company spanning contact lenses, IOLs (enVista, Toric), and LASIK excimer technology through Technolas. CTO Madhu Ayyagari's former employer; competes in refractive correction across multiple modalities.

Regional players

  • Schwind eye-tech-solutions: German manufacturer of excimer (AMARIS) and femtosecond lasers for refractive surgery. Strong in European refractive surgery markets where TECLens already has trial sites, making it a relevant competitive reference in shared geographies.

Emerging players

  • LENSAR: US-based company commercializing the ALLY robotic cataract and refractive system, also pursuing presbyopia-correcting IOLs. Smaller, growth-stage competitor targeting overlapping refractive and presbyopia correction indications.

Market position

Strengths5 records

Weaknesses5 records

Competitive moat5 records

Key risks6 records

Key highlights7 records

Customer concentration

TECLens social profiles

Digital presence

TECLens financial estimates

Financial estimate

Revenue estimate

Valuation estimate

TECLens leadership team

Management profile

Number of profiles

TECLens funding detail

Funding detail

Funding overview

Funding rounds5 records

Investors4 records

Funding detail is available on the Subscription and Enterprise plan.Contact sales →

TECLens M&A and investment

M&A and investment

M&A

Investments

M&A and investment is available on the Subscription and Enterprise plan.Contact sales →

Frequently asked questions about TECLens

What does TECLens do?

TECLens develops the qCXL™ system — a proprietary non-invasive corneal cross-linking platform centered on the single-use disposable CXLens® scleral contact lens, a control console, a proprietary trans-epithelial riboflavin formulation, and a computational treatment planning suite. The platform uses patterned ultraviolet light combined with real-time ultrasound monitoring to strengthen and reshape the cornea, addressing refractive errors (presbyopia, myopia, hyperopia, astigmatism) and keratoconus without cutting or removing tissue.

Is TECLens a public or private company?

TECLens is a private company. It is classified as venture growth investor backed and is currently operating.

When was TECLens founded?

TECLens was founded in 2013. It employs 11 to 50 people.

Where is TECLens based?

TECLens is headquartered in Stamford, United States, in the North America region.

How does TECLens make money?

Two revenue lines are on record. Medical Device Sales are the primary driver. The others are consumables.

Who are TECLens's main competitors?

Direct peers on record are Glaukos Corporation (Avedro), Peschke Medizintechnik, Sooft Italia and Ziemer Ophthalmic Systems. Broad incumbents are Carl Zeiss Meditec, Alcon, Johnson & Johnson Vision and Bausch + Lomb. Schwind eye-tech-solutions is listed as a regional player. LENSAR is listed as an emerging player.

Does TECLens have an API?

No public API is recorded for TECLens.

What industry is TECLens in?

TECLens's product category is Ophthalmic Medical Devices. Its primary akta.pro industry code is HLAHAJAK, Cornea & External Disease Surgical Devices (Keratoplasty Tools, Cross-Linking Systems, Amniotic Membrane Delivery), with a secondary code of HLAHAJAG, Refractive Surgery Systems (Excimer/Femtosecond Lasers, Phakic IOL Systems, Wavefront/Guidance). Its NAICS code is 339115 and its SIC code is 3851.

Unlock the full company data

50 free credits on sign-up, no credit card required.

Contact sales
Live signals
Eyes On EyecareTECLens study treats first patient for noninvasive refractive vision correctionTECLens, Inc. has treated its first patient in a first-in-human clinical trial evaluating its quantitative corneal crosslinking (qCXL) technology for non-invasive refractive vision correction. The qCXL procedure is an in-office treatment that uses a fiber optic-connected scleral contact lens to deliver UV light to the cornea, reshaping it to improve vision in approximately 30 minutes. The company plans to release additional details about the trial as more patients are enrolled and treated.Medical Device NetworkTECLens begins first-in-human trial for qCXL vision correction technologyTECLens has commenced the first-in-human clinical trial for its quantitative corneal crosslinking (qCXL) technology, administering treatment to the initial patient for non-invasive refractive vision correction. The qCXL platform strengthens the cornea without removing tissue by creating targeted molecular bonds through patterned ultraviolet light, using a customized treatment planning engine and real-time ultrasound monitoring for precision. The trial will primarily focus on patients with refractive errors, particularly presbyopia, a condition affecting approximately two billion people worldwide, with the company positioning the technology as a potential first-line, in-office treatment alternative to surgery.Eyewire+TECLens Initiates First-in-Human Trial of Quantitative Corneal Crosslinking ProcedureTECLens has initiated its first-in-human clinical trial for qCXL, a noninvasive vision correction technology designed to reshape the cornea without surgical tissue removal. The CXLens system utilizes personalized UV light and real-time monitoring to treat refractive errors, particularly presbyopia, in an office setting.Business Wire BlogFirst Patient Treated in TECLens First-in-Human Clinical Study of Revolutionary Non-Invasive Vision Correction TechnologyTECLens, Inc. announced the treatment of its first patient in a first-in-human clinical trial evaluating its qCXL™ technology, a non-invasive vision correction platform that strengthens the cornea through targeted molecular bonding rather than surgical tissue removal. The CXLens® system, which uses patterned ultraviolet light with real-time biomechanical monitoring, completed its initial in-office procedure as part of a study focused on refractive errors and presbyopia, a condition affecting nearly 2 billion people worldwide. The company expects the technology to expand access to vision correction by enabling treatment in exam rooms rather than operating rooms.Pulse 2.0TECLens: $9.3 Million (Series A) Raised For Advancing Non-Invasive Refractive TechnologyTECLens raised $9.3 million in a Series A round co-led by Johnson & Johnson Innovation and Yonjin Capital. The funding supports clinical development of its non-incisional refractive correction using corneal cross-linking, with a focus on presbyopia. Future applications include pediatric myopia and other refractive errors.ClearvisionforyouJohnson & Johnson Backs TECLens: Pushing Eye Care ForwardJohnson & Johnson co-led the Series A funding for TECLens, an early-stage start-up developing a non-incisional refractive vision correction procedure using corneal cross-linking technology. The investment aims to leverage J&J's expertise in eye health to bring a personalized, office-based treatment to market for conditions such as presbyopia and keratoconus. This strategic move supports J&J's broader ambition to expand its portfolio of innovative ophthalmology solutions.Daily Medical NewsJohnson & Johnson invests in TECLens refractive technology startupJohnson & Johnson Innovation closed a Series A funding round as co-lead investor in TECLens, a startup developing a non-incisional refractive correction procedure using corneal cross-linking. The treatment, indicated for presbyopia in initial clinical studies, aims to reshape the cornea without laser ablation. J&J plans to track progress toward clinical development milestones.SecSEC FORM DTECLens, Inc. filed a Form D with the SEC to report an exempt securities offering under Rule 506(b) with a total offering amount of $9,278,350. The company has already sold $4,278,349 worth of equity securities and intends to use up to $411,000 of the proceeds for director expense reimbursements and CEO consulting fees.PR NewswireTECLens and SERVImed Industrial Spa Announce a Partnership to Pursue U.S. FDA Approval for Trans-epithelial Corneal Cross-LinkingTECLens and SERVImed announced a partnership to develop a combination product combining CXLens and RIBOCROSS for keratoconus treatment. The product targets over a million US patients, and SERVImed's RIBOCROSS holds an FDA orphan drug designation.